You just read:

Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer

News provided by

Regeneron Pharmaceuticals, Inc.

Mar 10, 2011, 04:05 EST